

14th August, 2020

To,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001

Dear Sir,

Sub: Outcome of the Board Meeting
BSE Code: 531210

The Meeting of Board of Directors was held on Friday, 14th August, 2020 at 2.30 P.M. The Board of Directors discussed and/or approved the following:

1. The Board considered and approved Un-audited Financial Results for the quarter ended 30th June, 2020 as per Regulation 33 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. In this regard, the Statutory Auditors have carried out "Limited Review" of the above results. Please find enclosed copy of unaudited financial results along with Limited Review Report for the quarter ended 30th June, 2020.
2. The Board approved Director's Report for the year ended 31st March, 2020.
3. The Board also approved Management Discussion Report, Corporate Governance Report, CEO's certification & other documents for the year ended 31st March, 2020.
4. The Board took note of Secretarial Audit Report issued by M/s. Sanjay Dholakia & Associates, Practising Company Secretaries for the year ended 31st March, 2020.
5. The Board discussed and finalized the date, time and mode of 34th Annual General Meeting of the Company on 30th September, 2020 at 2.30 P.M. through video conference or other audio-visuals means and also approved the draft notice of forthcoming Annual General Meeting of the Company. The Board also approved the appointment of Ms. Ashwini Vaze, Practising Company Secretary, as a Scrutinizer for e-voting at 34th AGM.
6. The Board also approved and finalized that the Register of Members will remain closed for the purpose of 34th Annual General Meeting of the Company from 23rd September, 2020 to 30th September, 2020 (both days inclusive). Notice relating to Book Closure will be sent separately.

Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006



7. Further pursuant to Rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed 23rd day of September, 2020 as the Cut-Off date for the purpose of determining the eligible shareholders (holding shares either in physical form or in dematerialized form) to cast their votes electronically between 27th September, 2020 (9:00 A.M. IST) to 29th September, 2020 (5:00 P.M. IST), and approved the NSDL as agent for e-voting,
8. The Board also considered and approved appointment of M/s. Sanjay Dholakia & Associates, Practising Company Secretaries as the Secretarial Auditor for the financial year ended 31st March, 2021.

The Board Meeting commenced at 2:30 p.m. and concluded at 4.00 p.m.

This is for your information and record.

Thanking you,

Yours faithfully,

FOR COLINZ LABORATORIES LTD

DR. MANI L.S.

Director- Legal, Company Secretary & Compliance Officer

DIN : 00825886



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

Tel:- +91-22-2566 8002 / 8003 Fax :- +91-22-2566 8006



VORA & ASSOCIATES
CHARTERED ACCOUNTANTS

101-103, REWA CHAMBERS
31, NEW MARINE LINES
MUMBAI - 400 020. INDIA

☎ 022-2200 5933 - 2200 5934
022-2206 3289 - 6615 5599
🌐 www.cavoras.com
✉ office@cavoras.com
cavoras@gmail.com

Independent Auditor's Review Report on Unaudited Quarterly Financial Results

To
The Board of Directors,
COLINZ LABORATORIES LIMITED.

We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **COLINZ LABORATORIES LIMITED** ('the Company') for the quarter ended 30th June, 2020 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34') prescribed u/s 133 of the Companies Act, 2013 ('the Act'), SEBI Circular CIR/CF/FAC/62/2016 dated 05/07/2016 (hereinafter referred to as the 'the SEBI Circular') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Statements Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Act read with relevant Rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VORA & ASSOCIATES
CHARTERED ACCOUNTANTS
(ICAI Firm Reg. No.: 111612W)


RONAK A. RAMBHIA
PARTNER

(Membership No.: 140371)



UDIN: 20140371AAAADQ2284

PLACE: MUMBAI

DATED: 14 AUG 2020

COLINZ LABORATORIES LIMITED.

(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2020

"(Rs. In Lakhs)"

S. No.	Particulars	Un-Audited		Audited	
		Quarter ended		Quarter ended	YEAR ENDED
		30-Jun-20	30-Jun-19	31-Mar-20	31-Mar-20
1	(a) Revenue from Operation	141.56	202.47	165.48	760.33
3	(b) Other Income	3.22	2.86	5.06	13.49
3	Total Income from Operation	144.78	205.33	170.54	773.82
4	Expenses				
	(a) Cost Of Material Consumed	9.64	22.08	14.85	81.56
	(b) Purchase of Stock in Trade	22.64	45.90	36.00	180.83
	(c) Change in Inventories Of Finished Goods and Work in Progress	34.86	4.80	2.89	12.02
	(d) Employee Benefit Expenses	43.11	86.41	88.02	352.03
	(e) Finance Cost	2.26	2.86	1.08	6.68
	(f) Depreciation & Amortisation Expenses	4.62	4.84	4.97	19.48
	(g) Other Expenses	20.98	31.97	22.01	103.62
	Total Expenses	138.11	198.86	169.82	756.22
5	Profit/(Loss) Before exceptional items and tax (3-4)	6.67	6.47	0.72	17.60
6	Exceptional items	-	-	-	-
7	Profit/(Loss) before tax (5-6)	6.67	6.47	0.72	17.60
8	Tax Expenses (Provision for Taxation) Current tax				
	i) Current Tax	1.25	1.25	4.25	7.00
	ii) Deferred Tax	-	-	(2.44)	(2.44)
	iii) Tax for earlier years	-	-	-	-
	iv) MAT Credit of Earlier years	-	-	-	-
9	Profit/(Loss) for the period from continuing operations(7-8)	5.42	5.22	(1.09)	13.04
10	Profit/(Loss) for the period	5.42	5.22	(1.09)	13.04
11	Other Comprehensive Income (Net of Tax)				
	A) Item that will not be reclassified to Profit or Loss Account				
	i) Change in fair value of investment in Equity Instruments	8.50	(1.29)	(16.62)	(13.53)
12	Total Comprehensive Income for the period (10+11) Comprising	13.92	3.93	(17.71)	(0.49)
13	Earning per equity share (for Continuing operation) (In Rs.)				
	i) Basic	0.30	0.09	-	-
	ii) Diluted	0.30	0.09	-	-



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128



Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com

NOTES TO THE FINANCIAL RESULTS :-


- 1) The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 14th Aug, 2020.
- 2) COVID-19 has caused significant disturbance and slow down of the Economic activities. Our operations are also affected due to Lockdowns both at National and Local levels. Supply chain is also impacted. Operations at Factory and Office continue though with limited attendance. Company's products are prescription oriented and hence non availability of consultant doctors in their clinics has affected the top line of the Company to the tune of 20-25% during the first quarter of FY 20-21. While the future impact of COVID-19 is difficult to project, Company's status as a going concern remains/ and expected to remain unaffected due to various cost cutting measures adopted by the Company to offset the impact of the reduction in the top line.
- 3) The above results of the Company has been reviewed by the Statutory Auditors and they have issued a Limited Review Report on the same.
- 4) The Company is primarily engaged in the business of manufacturing Pharmaceutical Formulations and there is no other reportable segment.
- 5) Previous figures have been regrouped/ rearranged , wherever necessary.

MUMBAI.
14th Aug, 2020.



For and on behalf of the Board
COLINZ LABORATORIES LTD.

CIN NO. L24200MH1986PLC041128


Dr. Mani L. S. (Din No : 00825886)
Director, Legal, Company Secretary



Colinz Laboratories Limited

CIN NO- L24200MH1986PLC041128

Corp.Off.: A/101, Pratik Estate, Next to Fortis Hospital, Mulund Link Road, P. Box No. 17339 Mumbai - 400 078. INDIA

E-mail : colinzlabs@yahoo.com / colinzlabs@gmail.com